Johnson & Johnson (NYSE:JNJ) Shares Sold by Alera Investment Advisors LLC

Posted by Defense World Staff on Jul 30th, 2023

Alera Investment Advisors LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 7.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 7,443 shares of the company’s stock after selling 618 shares during the quarter. Alera Investment Advisors LLC’s holdings in Johnson & Johnson were worth $1,154,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. LCM Capital Management Inc boosted its stake in Johnson & Johnson by 0.7% during the fourth quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock worth $1,667,000 after buying an additional 61 shares during the last quarter. Arbor Investment Advisors LLC lifted its stake in shares of Johnson & Johnson by 2.3% in the 4th quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock valued at $476,000 after purchasing an additional 61 shares during the last quarter. Sierra Capital LLC lifted its stake in shares of Johnson & Johnson by 0.6% in the 4th quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock valued at $1,773,000 after purchasing an additional 61 shares during the last quarter. Lockerman Financial Group Inc. lifted its stake in shares of Johnson & Johnson by 2.4% in the 4th quarter. Lockerman Financial Group Inc. now owns 2,684 shares of the company’s stock valued at $474,000 after purchasing an additional 62 shares during the last quarter. Finally, OneAscent Financial Services LLC lifted its stake in shares of Johnson & Johnson by 3.3% in the 1st quarter. OneAscent Financial Services LLC now owns 1,986 shares of the company’s stock valued at $308,000 after purchasing an additional 63 shares during the last quarter. Institutional investors and hedge funds own 67.57% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $174.48 on Friday. The firm has a market capitalization of $453.43 billion, a PE ratio of 35.32, a price-to-earnings-growth ratio of 2.91 and a beta of 0.55. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $181.04. The stock’s 50-day simple moving average is $161.76 and its 200-day simple moving average is $161.21. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.62 by $0.18. The company had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a return on equity of 37.01% and a net margin of 13.35%. The firm’s revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.59 earnings per share. As a group, equities research analysts forecast that Johnson & Johnson will post 10.76 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be given a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 2.73%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 96.36%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares in the company, valued at $15,092,484. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares in the company, valued at $10,549,440. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 47,163 shares of company stock worth $7,928,856. 0.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have recently commented on JNJ. Morgan Stanley reaffirmed an “equal weight” rating and issued a $187.00 price target on shares of Johnson & Johnson in a research note on Friday, July 21st. Stifel Nicolaus increased their target price on Johnson & Johnson from $165.00 to $175.00 in a research note on Friday, July 21st. StockNews.com initiated coverage on Johnson & Johnson in a research note on Thursday, May 18th. They set a “strong-buy” rating on the stock. Citigroup initiated coverage on Johnson & Johnson in a report on Tuesday, May 30th. They set a “buy” rating and a $185.00 price target on the stock. Finally, Raymond James upped their price target on Johnson & Johnson from $181.00 to $184.00 and gave the stock an “outperform” rating in a report on Monday, July 24th. Eight investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $171.60.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.